MeSH D005923 - focal segmental glomerulosclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cyclosporine | Cyclosporine |  | 2005-03-25 |  |  |
| Padagis | Cyclosporine | Cyclosporine |  | 2003-10-07 |  |  |
| Mylan | Cyclosporine | Cyclosporine |  | 2022-02-02 |  |  |
| Sandoz | Cyclosporine | Cyclosporine |  | 2000-01-13 |  |  |
| AbbVie | Cyclosporine | Cyclosporine |  | 2000-03-03 |  |  |
| Cyclosporine | Gengraf |  | 2000-05-12 |  |  | |
| Cyclosporine | Restasis Multidose | 2024-08-27 | 2002-12-23 |  |  | |
| Novartis | Cyclosporine | Neoral |  | 1995-07-14 | $379 M | Q2/19-Q2/22 |
| Cyclosporine | Sandimmune |  | 1983-11-14 |  |  | |
| Sun Pharmaceutical Industries | Cyclosporine | Cequa | 2033-08-23 | 2018-08-14 |  |  |
| Apotex | Cyclosporine | Cyclosporine |  | 2002-05-09 |  |  |
| Strides Pharma Global | Cyclosporine | Cyclosporine |  | 2022-08-02 |  |  |
| Hikma Pharmaceuticals | Cyclosporine | Cyclosporine |  | 1999-10-29 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%2/4
Phase 2
33%9/27
Phase 3
22%4/18
Approved: 2Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use